Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Suits Complicate Merck Spin-Off Plans, Position In Medicare Debate

Executive Summary

The unsealing of two "whistleblower" complaints filed against Medco Health Solutions is the latest complication in Merck's plans to spin-off the pharmacy benefit management division
Advertisement

Related Content

Medco Faces Third “Whistleblower” Case; Medicaid Rebate Law Is Focus
FTC Review Of Caremark Deal Will Be Fourth Look At PCS
Retail Pharmacy Class Actions Versus PBMs Challenge “No Mail” Clauses
Medco Health Valued At $6 Bil. Heading Into Aug. 19 Spin-Off
Medco Reports New Problems With Mail-Order Recordkeeping
Medco Is Meeting Merck Market Share Targets; Spin-Off Plan Moves Ahead
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
CDC Advocates All-IPV Immunization Schedule; Combo Development Heats Up
CDC Advocates All-IPV Immunization Schedule; Combo Development Heats Up
Caremark Adds Site Management To Its Services With Protocare Partnership
Advertisement
UsernamePublicRestriction

Register

PS042051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel